Vascular targeted nanoparticles for imaging and treatment of brain tumors

Clinical Cancer Research

Volumn 12, Issue 22, 2006, Pages 6677-6686

  Reddy, G Ramachandra ^a   Bhojani, Mahaveer S ^a   McConville, Patrick ^b   Moody, Jonathan ^b   Moffat, Bradford A ^a   Hall, Daniel E ^a   Kim, Gwangseong ^b   Koo, Yong Eun L ^b   Woolliscroft, Michael J ^a   Sugai, James V ^a   Johnson, Timothy D ^b   Philbert, Martin A ^b   Kopelman, Raoul ^b   Rehemtulla, Alnawaz ^a   Ross, Brian D ^a,b  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IRON OXIDE; NANOPARTICLE; PHOTOFRIN; PHOTOSENSITIZING AGENT;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN TUMOR; CANCER CELL; CONTRAST ENHANCEMENT; CONTROLLED STUDY; CYTOTOXICITY; DRUG BINDING; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG EXPOSURE; HUMAN; HUMAN CELL; IN VITRO STUDY; NEUROIMAGING; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PHOTODYNAMIC THERAPY; PHOTOSENSITIVITY; PRIORITY JOURNAL; RAT; SURVIVAL RATE; TUMOR VASCULARIZATION;

ANGIOGRAPHY; ANIMALS; BLOOD VESSELS; BRAIN NEOPLASMS; DIAGNOSTIC IMAGING; DIHEMATOPORPHYRIN ETHER; DRUG ADMINISTRATION ROUTES; DRUG CARRIERS; FERRIC COMPOUNDS; GLIOMA; HUMANS; MALE; NANOPARTICLES; NANOTECHNOLOGY; PHOTOCHEMOTHERAPY; PHOTOSENSITIZING AGENTS; RATS; SURVIVAL ANALYSIS; TUMOR CELLS, CULTURED;

EID: 33845300821     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-06-0946     Document Type: Article

References (46)

1. Henderson BW, Dougherty TJ. How does photodynamic therapy work? Photochem Photobiol 1992;55:145-57.
2. Abels C. Targeting of the vascular system of solid tumours by photodynamic therapy (PDT). Photochem Photobiol Sci 2004;3:765-71.
3. Bisland SK, Singh D, Gariepy J. Potentiation of chlorin e6 photodynamic activity in vitro with peptide-based intracellular vehicles. Bioconjug Chem 1999;10:982-92.
4. Chaloin L, Bigey P, Loup C, et al. Improvement of porphyrin cellular delivery and activity by conjugation to a carrier peptide. Bioconjug Chem 2001;12:691-700.
5. Del Governatore M, Hamblin MR, Shea CR, et al. Experimental photoimmunotherapy of hepatic metastases of colorectal cancer with a 17.1A chlorin (e6) immunoconjugate. Cancer Res 2000;60:4200-5.
6. Sharman WM, van Lier JE, Allen CM. Targeted photodynamic therapy via receptor mediated delivery systems. Adv Drug Deliv Rev 2004;56:53-76.
7. van Dongen GA, Visser GW, Vrouenraets MB. Photosensitizer-antibody conjugates for detection and therapy of cancer. Adv Drug Deliv Rev 2004;56:31-52.
8. Chen B, Pogue BW, Hasan T. Liposomal delivery of photosensitising agents. Expert Opin Drug Deliv 2005;2:477-87.
9. Ichikawa K, Hikita T, Maeda N, et al. Antiangiogenic photodynamic therapy (PDT) by using long-circulating liposomes modified with peptide specific to angiogenie vessels. Biochim Biophys Acta 2005;1669:69-74.
10. McCarthy JR, Perez JM, Bruckner C, Weissleder R. Polymeric nanoparticle preparation that eradicates tumors. Nano Lett 2005;5:2552-6.
11. Tang W, Xu H, Kopelman R, Philbert MA. Photodynamic characterization and in vitro application of methylene blue-containing nanoparticle platforms. Photochem Photobiol 2005;81:242-9.
12. Loo C, Lowery A, Halas N, West J, Drezek R. Immunotargeted nanoshells for integrated cancer imaging and therapy. Nano Lett 2005;5:709-11.
13. Pitsillides CM, Joe EK, Wei X, Anderson RR, Lin CP. Selective cell targeting with light-absorbing microparticles and nanoparticles. Biophys J 2003;84:4023-32.
14. Konan YN, Berton M, Gurny R, Allemann E. Enhanced photodynamic activity of meso-tetra(4-hydroxyphenyl) porphyrin by incorporation into sub 200 nm nanoparticles. Eur J Pharm Sci 2003;18:241-9.
15. Moffat BA, Reddy GR, McConville P, et al. A novel polyacrylamide magnetic nanoparticle contrast agent for molecular imaging using MRI. Mol Imaging 2003;2:324-32.
16. Weissleder R, Elizondo G, Wittenberg J, Rabito CA, Bengele HH, Josephson L. Ultrasmall superparamagnetic iron oxide: characterization of a new class of contrast agents for MR imaging. Radiology 1990;175:489-93.
17. Weissleder R, Elizondo G, Wittenberg J, Lee AS, Josephson L, Brady TJ. Ultrasmall superparamagnetic iron oxide: an intravenous contrast agent for assessing lymph nodes with MR imaging. Radiology 1990;175:494-8.
18. Arap W, Pasqualini R, Ruoslahti E. Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model. Science 1998;279:377-80.
19. Zitzmann S, Ehemann V, Schwab M. Arginine-glycine-aspartic acid (RGD) -peptide binds to both tumor and tumor-endothelial cells in vivo. Cancer Res 2002;62:5139-43.
20. Porkka K, Laakkonen P, Hoffman JA, Bernasconi M, Ruoslahti E. A fragment of the HMGN2 protein homes to the nuclei of tumor cells and tumor endothelial cells in vivo. Proc Natl Acad Sci U S A 2002;99:7444-9.
21. Akerman ME, Chan WC, Laakkonen P, Bhatia SN, Ruoslahti E. Nanocrystal targeting in vivo. Proc Natl Acad Sci U S A 2002;99:12617-21
22. Christian S, Pilch J, Akerman ME, Porkka K, Laakkonen P, Ruoslahti E. Nucleolin expressed at the cell surface is a marker of endothelial cells in angiogenic blood vessels. J Cell Biol 2003;163:871-8.
23. Ruoslahti E. Vascular zip codes in angiogenesis and metastasis. Biochem Soc Trans 2004;32:397-402.
24. Ruoslahti E, Duza T, Zhang L. Vascular homing peptides with cell-penetrating properties. Curr Pharm Des 2005;11:3655-60.
25. Chenevert TL, Stegman LD, Taylor JM, et al. Diffusion magnetic resonance imaging: an early surrogate marker of therapeutic efficacy in brain tumors. J Natl Cancer Inst 2000;92:2029-36.
26. Moffat BA, Chenevert TL, Lawrence TS, et al. Functional diffusion map: a noninvasive MRI biomarker for early stratification of clinical brain tumor response. Proc Natl Acad Sci U S A 2005;102:5524-9.
27. Hamstra DA, Chenevert TL, Moffat BA, et al. Evaluation of the functional diffusion map as an early biomarker of time-to-progression and overall survival in high-grade glioma. Proc Natl Acad Sci U S A 2005;102:16759-64.
28. Le Bihan D, Breton E, Lallemand D, Grenier P, Cabanis E, Laval-Jeantet M. MR imaging of intravoxel incoherent motions: application to diffusion and perfusion in neurologic disorders. Radiology 1986;161:401-7.
29. Plaks V, Koudinova N, Nevo U, et al. Photodynamic therapy of established prostatic adenocarcinoma with TOOKAD: a biphasic apparent diffusion coefficient change as potential early MRI response marker. Neoplasia 2004;6:224-33.
30. Roth Y, Tichler T, Kostenich G, et al. High-b-value diffusion-weighted MR imaging for pretreatment prediction and early monitoring of tumor response to therapy in mice. Radiology 2004;232:685-92.
31. Perria C, Capuzzo T, Cavagnaro G, et al. Fast attempts at the photodynamic treatment of human gliomas. J Neurosurg Sci 1980;24:119-29.
32. Kaye AH, Morstyn G, Brownbill D. Adjuvant high-dose photoradiation therapy in the treatment of cerebral glioma: a phase 1-2 study. J Neurosurg 1987;67:500-5.
33. Kostron H, Weiser G, Fritsch E, Grunert V. Photodynamic therapy of malignant brain tumors: clinical and neuropathological results. Photochem Photobiol 1987;46:937-43.
34. Muller PJ, Wilson BC. Photodynamic therapy of malignant brain tumours. Can J Neurol Sci 1990;17:193-8.
35. Muller PJ, Wilson BC. Photodynamic therapy for malignant newly diagnosed supratentorial gliomas. J Clin Laser Med Surg 1996;14:263-70.
36. Popovic EA, Kaye AH, Hill JS. Photodynamic therapy of brain tumors. Semin Surg Oncol 1995;11:335-45.
37. Stylli SS, Howes M, MacGregor L, Rajendra P, Kaye AH. Photodynamic therapy of brain tumours: evaluation of porphyrin uptake versus clinical outcome. J Clin Neurosci 2004;11:584-96.
38. Stylli SS, Kaye AH, Macgregor L, Howes M, Rajendra P. Photodynamic therapy of high grade glioma - long term survival. J Clin Neurosci 2005;12:389-98.
39. Merkel PB, Kearns DR. Radiationless decay of singlet molecular oxygen in solution, an experimental and theoretical study of electronic-to-vibrational energy transfer. J Am Chem Soc 1972;94:7244-53.
40. Usui Y, Tsukada M, Nakamura H. Kinetic studies of photosensitized oxygenation by singlet oxygen in aqueous micellar solutions. Chem Soc Jpn 1978;51:379-84.
41. 3 incorporated in polyacrylamide PEBBLES. Sens Actuators B Chem 2003;90:82-9.
42. Moffat BA, Chenevert TL, Meyer CR, et al. The functional diffusion map: an imaging biomarker for early prediction of cancer treatment outcome. Neoplasia 2006;8:259-66.
43. Peng O, Nesland JM. Effects of photodynamic therapy on tumor stroma. Ultrastruct Pathol 2004;28:333-40.
44. Denekamp J. Review article: angiogenesis, neovascular proliferation, and vascular pathophysiology as targets for cancer therapy. Br J Radiol 1993;66:181-96.
45. Shimizu K, Asai T, Oku N. Antineovascular therapy, a novel antiangiogenic approach. Expert Opin Ther Targets 2005;9:63-76.
46. Spikes JD. Quantum yields and kinetics of the photobleaching of hematoporphyrin, Photofrin II, tetra (4-sulfonatophenyl)-porpbine, and uroporphyrin. Photochem Photobiol 1992;55:797-808.